Open Access Articles- Top Results for Amylin Pharmaceuticals

Amylin Pharmaceuticals

Amylin Pharmaceuticals
Industry Biotechnology
Founded 1987
Headquarters San Diego, California, USA
Key people
Daniel M. Bradbury[1]
Products Symlin (pramlintide)
Byetta (exenatide)
Revenue 11pxUS$758M (FY 2009)[2]
11pxUS$-173M (FY 2009)[2]
#redirect Template:If affirmed 11pxUS$-186M (FY 2009)[2]
Total assets 11pxUS$1.73B (FY 2009)[3]
Total equity 11pxUS$423M (FY 2009)[3]
Number of employees
1,900 [1]
Slogan Challenging Science, Changing Lives.

Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces three drugs, Symlin (pramlintide acetate) and Byetta (exenatide) and Bydureon (exenatide extended-release). Amylin also produces an analog of human leptin, metreleptin.[4]

In July 2012, Bristol-Myers Squibb announced it would acquire Amylin Pharmaceuticals for $5.3 billion.[5]

In December 2013, Amylin was acquired by AstraZeneca.[6]


External links

Lua error in package.lua at line 80: module 'Module:Buffer' not found.